- Gus Cairns | 18 April 2019
A study presented at this year’s Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle found that young people born with HIV performed worse when given certain
neurological/psychological tasks than HIV-negative ...
- Liz Highleyman | 11 April 2019
An experimental monoclonal antibody called PGT121 led
to viral suppression that lasted for up to six months in HIV-positive people
who started with a low viral load, according to results from a ...
- Keith Alcorn | 05 April 2019
Most health problems in people living with HIV in two large
cohorts can be classified in six clusters, with cardiovascular disease,
metabolic problems, sexually transmitted infections and mental health
conditions being the most ...
- Michael Carter | 29 March 2019
Incidence of acute hepatitis C virus (HCV) among men who have sex with men (MSM) who use pre-exposure prophylaxis (PrEP) in Lyon increased tenfold between 2016 and 2017, according to ...
- Liz Highleyman | 28 March 2019
A growing number of people with HIV in the US are dying from opioid
overdoses, according to a presentation at the Conference on Retroviruses and
Opportunistic Infections (CROI 2019) this month in ...
- Roger Pebody | 27 March 2019
Much of the excessive cost of prescription drugs in the
United States falls on patients, and national surveillance data has now found that this has a real impact on HIV treatment
outcomes. ...
- Gus Cairns | 22 March 2019
A study from Peru’s capital, Lima, has found that the sexual partners of transgender women there are largely heterosexual, cisgender men who rarely have sex with other men. The study ...
- Michael Carter | 19 March 2019
A point-of-care
urine test can accurately determine if a person is adherent to tenofovir-based
pre-exposure prophylaxis (PrEP), according to research presented to the recent Conference on Retroviruses and Opportunistic Infections (CROI 2019) ...
- Gus Cairns | 13 March 2019
Two studies in monkeys of experimental pre-exposure prophylaxis
(PrEP) regimens featuring the drug tenofovir alafenamide (TAF) produced differing
results when presented at last week’s Conference on Retroviruses and Opportunistic Infections (CROI 2019) ...
- Michael Carter | 13 March 2019
Virological
response rates were excellent among patients receiving second-line antiretroviral
therapy (ART) based on dolutegravir, even when regimens included a nucleoside/nucleotide
reverse transcriptase inhibitor (NRTI) to which there was pre-existing
resistance, according to research ...
- Liz Highleyman | 13 March 2019
People living with HIV who have a longer duration of
detectable viral load and those with low CD4 cell counts have a higher
likelihood of developing liver cancer in the absence of ...
- Roger Pebody | 12 March 2019
“Thailand is progressing in the right direction to end AIDS,
but needs sustained political and policy commitment with a sense of urgency for
‘the last miles’,” Dr Praphan Phanuphak of the Thai ...
- Gus Cairns | 12 March 2019
Researchers have introduced genetic changes into human T-cells
that make them virtually immune to HIV infection, and the viral load in
HIV-positive people who are inoculated with these cells returns more slowly
when ...
- Krishen Samuel | 12 March 2019
Undetectable =
Untransmittable (U=U) is a human rights issue, Dr Carrie Foote told the
Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle last
week. “All people living with HIV have a ...
- Liz Highleyman | 12 March 2019
People living with HIV, especially women, may develop
lung cancer at an earlier age and with a less extensive smoking history than
people in the general population, according to a study presented ...
- Roger Pebody | 12 March 2019
Asking people living with HIV in Malawi to pass on HIV
self-testing kits to their sexual partners was an effective way to encourage
partners to take a test, but linkage to care ...
- Carole Leach-Lemens | 12 March 2019
Co-administration of
dolutegravir-based antiretroviral therapy and short course (12 weeks) of rifapentine/isoniazid
(3HP) for people living with HIV needing preventative treatment for latent
tuberculosis (TB) infection was well tolerated with no adverse reactions, ...
- Carole Leach-Lemens | 12 March 2019
Women with high levels of
hepatitis B viraemia (>106IU/ml) who have co-infection with HIV had a more
than sixfold increased risk of having infants with HIV infection compared to
women with HIV alone ...
- Liz Highleyman | 11 March 2019
An experimental HIV capsid inhibitor appears safe and may
be able to be administered once every three months or less, according to results
from an early clinical trial presented at the Conference ...
- Keith Alcorn | 11 March 2019
One in six people not on treatment in a large South African
household survey already had drug-resistant HIV and more than half of those on
treatment had resistance to at least one ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...